Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,966 DKK | +0.46% | -2.12% | -8.79% |
Apr. 30 | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
Apr. 30 | Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment | MT |
Sales 2024 * | 19.67B 2.83B | Sales 2025 * | 23.53B 3.38B | Capitalization | 127B 18.26B |
---|---|---|---|---|---|
Net income 2024 * | 5.07B 728M | Net income 2025 * | 6.71B 964M | EV / Sales 2024 * | 5.13 x |
Net cash position 2024 * | 26.2B 3.76B | Net cash position 2025 * | 33.18B 4.77B | EV / Sales 2025 * | 3.99 x |
P/E ratio 2024 * |
25.4
x | P/E ratio 2025 * |
19.5
x | Employees | 2,204 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab A/S
1 day | +0.46% | ||
1 week | -2.12% | ||
Current month | -5.69% | ||
1 month | -5.78% | ||
3 months | +1.42% | ||
6 months | -1.28% | ||
Current year | -8.79% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.64% | 192 M€ | +13.78% | ||
1.28% | 49 M€ | +5.82% | ||
1.01% | 96 M€ | -1.46% | ||
0.75% | 18 M€ | +2.87% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 1,966 | +0.46% | 74,842 |
24-04-30 | 1,956 | -0.69% | 122,811 |
24-04-29 | 1,970 | +0.79% | 124,815 |
24-04-26 | 1,954 | +2.04% | 108,599 |
24-04-25 | 1,916 | -2.87% | 157,995 |
Delayed Quote Nasdaq Copenhagen, May 01, 2024 at 10:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.79% | 18.14B | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B | |
+310.48% | 8.78B |
- Stock Market
- Equities
- GMAB Stock